Credit: Cincinnati Children's
CINCINNATI – Researchers report in Nature Communications they figured out why air sacs in the lungs clog up with a thick substance called surfactant in a brutal disease called Pulmonary Alveolar Proteinosis (PAP), and they show taking cholesterol-busting pills called statins can effectively treat the disease.
That's good news for people with PAP because at present the current standard treatment is something called a whole lung lavage. Essentially, it involves flushing patient lungs to clear out the gunk–a procedure so invasive it requires putting people under general anesthesia. Furthermore, the procedure has to be repeated every time the lungs clog up, which translates into some pretty serious quality of life issues for patients.
Researchers at Cincinnati Children's Hospital Medical Center found out the culprit is cholesterol. Led by Bruce Trapnell, MD, director of the Translational Pulmonary Science Center, the team found out years ago that PAP is linked to disruption of cell regulation by a molecule called granulocyte-macrophage colony stimulating factor (GM-CSF). GM-CSF is crucial for the development of fully mature macrophage cells in the lungs, which are needed to clear away used surfactant–a substance important to lung function–so that people can breathe.
In their new study of PAP patients and mouse models of the disease, the researchers uncovered a more precise reason that disruption of cell regulation by GM-CSF triggers PAP. It's because cell dysregulation reduces the ability of macrophages to process and clear out cholesterol, allowing its levels to build up. This contributes to the accumulation of surfactant that causes PAP and hinders breathing, according to study authors.
"Showing that the pathogenic driver of the disease is disruption of cholesterol homeostasis in these patients will change thinking in the PAP field," explains Trapnell. "Now that we know cholesterol in macrophages is a target for therapeutic development, repurposing statins is a pretty straight forward pharmacological approach for treating people with PAP."
Clinical Trial Planned
The findings are expected to lead to a clinical trial to test statin therapy in larger numbers of people suffering from PAP, said Trapnell. The current study tested statin therapy in two adult patients and in genetically engineered mouse models of PAP.
In both human patients and animal models of PAP, stain therapy was associated with improved cholesterol balance in pulmonary macrophage cells and allowed surfactant to be cleared from lung air sacs. This improved respiratory function in the adult patients and in the laboratory models. Those tests were the result of earlier experiments on mouse pulmonary macrophages and cells donated from patients.
###
First author on the study is Cormac McCarthy, MD, PhD, and a Rare Lung Diseases Consortium Scholar in the Translational Pulmonary Science Center at Cincinnati Children's.
Funding support for the study came in part from the National Institutes of Health/National Heart, Lung, and Blood Institute (R01085453, HL118161, HL136543), and a National Center for Advancing Translational Science grant through the National Heart, Lung, and Blood Institute (HL127672).
About Cincinnati Children's
Cincinnati Children's Hospital Medical Center ranks second in the nation among all Honor Roll hospitals in U.S. News and World Report's 2018-2019 Best Children's Hospitals ranking. In addition, Cincinnati Children's ranks first in the pediatric specialties of cancer and gastroenterology/GI surgery care, and among the top five pediatric hospitals in nine of 10 specialties. Founded in 1883, Cincinnati Children's vision is to be the leader in improving child health, through patient care, research and education.
Media Contact
Nick Miller
[email protected]
513-803-6035
@CincyChildrens
http://www.cincinnatichildrens.org
Related Journal Article
http://dx.doi.org/10.1038/s41467-018-05491-z
